Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the transcript. The company has completed its product development and investments for expansion, indicating no immediate capital requirement. Management focuses on improving capacity utilization and product mix rather than seeking new external funding. No explicit plans for raising funds via debt or equity were discussed during the call.

Any current/future capex/capital investment/strategic investment?

The company has completed major investments related to new product development and plant trials primarily in Q1 and Q2 of FY24. Currently, no significant ongoing capital expenditures or investments are indicated; process stabilization is in place. Expansion or capacity enhancement is expected mainly through better utilization and scaling up of existing capacities rather than fresh capex. Focus is on commercialization and scaling up of the newly developed high-value product, isosteric acid, rather than capital-intensive expansions. Future growth is expected to come from improved capacity utiliz

Future growth expectations in sales/revenue/volumes?

The company anticipates growth in volumes processed, with Q2 volume processed up 9% quarter-on-quarter. Topline growth is linked to raw material prices (refined oil price fluctuating between ₹90-140), making revenue difficult to quantify precisely. Capacity utilization is currently around 65%, expected to increase, supporting volume growth. New product, isosteric acid, expected to commence commercial shipments in Q3/Q4 FY24, contributing to growth. Paint industry seasonality affects quarterly sales; Q2 is traditionally lean. Expansion and product development investments are complete; focus now

Future growth expectations in earnings/operating earnings/profits/EPS?

Fairchem aims to achieve an EBITDA of around Rs.150 crores within the next couple of years, up from Rs.100 crores earlier, driven by margin recovery and volume growth. EBITDA margins are expected to improve gradually, targeting 14%-16% range, potentially reaching 15% by FY25 with stable raw material costs, improved capacity utilization (~65% currently), and new product sales (isosteric acid). Isosteric acid, a high-value export product (100% export, unique in India), is anticipated to start commercial shipments soon, contributing to margins and revenue growth. Volumes processed increased by 9%

Current/ Expected Orderbook/ Pending Orders?

The company has substantial orders already for the new high-value product, isosteric acid. Commercial shipments for isosteric acid are expected to commence once approvals and stability tests (90 to 120 days) are completed, likely starting in Q1 of the next year. Approvals for isosteric acid from major paint players, including Grasim and JSW, have already been secured. The company continues to retain all its existing customers and is optimistic about sales growth with new products. Orders tied up with new paint plants indicate improved demand and order inflows in the coming days.

IN US

Sale is live|00:00:00left today

Fairchem Organics LtdQ3 FY23Chemicals & Petrochemicals

Fairchem Organics Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹635P/E: 129.9Market Cap: ₹807 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

N/A

1 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company anticipates growth in volumes processed, with Q2 volume processed up 9% quarter-on-quarter.
→Topline growth is linked to raw material prices (refined oil price fluctuating between ₹90-140), making revenue difficult to quantify precisely.
→Capacity utilization is currently around 65%, expected to increase, supporting volume growth.
→New product, isosteric acid, expected to commence commercial shipments in Q3/Q4 FY24, contributing to growth.
→Paint industry seasonality affects quarterly sales; Q2 is traditionally lean.
→Expansion and product development investments are complete; focus now on improving quantities sold and operational efficiency.
→Expects gradual margin improvement to 15%-16% by FY25 due to product mix, capacity utilization, and raw material cost control.
→Long-term revenue growth aligned with growth in the organized paint industry and other diverse applications, especially for dimer acid and isosteric acid products.

Margin guidance

Category 1

→Fairchem aims to achieve an EBITDA of around Rs.150 crores within the next couple of years, up from Rs.100 crores earlier, driven by margin recovery and volume growth.
→EBITDA margins are expected to improve gradually, targeting 14%-16% range, potentially reaching 15% by FY25 with stable raw material costs, improved capacity utilization (~65% currently), and new product sales (isosteric acid).
→Isosteric acid, a high-value export product (100% export, unique in India), is anticipated to start commercial shipments soon, contributing to margins and revenue growth.
→Volumes processed increased by 9% quarter-on-quarter, and growth correlates with the paint industry, especially decorative segments.
→China dumping impact is receding, supporting margin recovery.
→The company sees margin improvement driven by a mix of product mix enhancement, raw material cost control, new products, and operating leverage, expecting more stable and standardized performance from Q3 FY24 onwards.
→EPS growth will follow operational improvements and margin expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or future fundraising through debt or equity in the transcript.
→The company has completed its product development and investments for expansion, indicating no immediate capital requirement.
→Management focuses on improving capacity utilization and product mix rather than seeking new external funding.
→No explicit plans for raising funds via debt or equity were discussed during the call.

Order book

→The company has substantial orders already for the new high-value product, isosteric acid.
→Commercial shipments for isosteric acid are expected to commence once approvals and stability tests (90 to 120 days) are completed, likely starting in Q1 of the next year.
→Approvals for isosteric acid from major paint players, including Grasim and JSW, have already been secured.
→The company continues to retain all its existing customers and is optimistic about sales growth with new products.
→Orders tied up with new paint plants indicate improved demand and order inflows in the coming days.

Capex plans

→The company has completed major investments related to new product development and plant trials primarily in Q1 and Q2 of FY24.
→Currently, no significant ongoing capital expenditures or investments are indicated; process stabilization is in place.
→Expansion or capacity enhancement is expected mainly through better utilization and scaling up of existing capacities rather than fresh capex.
→Focus is on commercialization and scaling up of the newly developed high-value product, isosteric acid, rather than capital-intensive expansions.
→Future growth is expected to come from improved capacity utilization, product mix, and market expansion, particularly with isosteric acid, rather than fresh large-scale capital investment.

How does Fairchem Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Fairchem Organics Ltd

Rev 3Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Fairchem Organics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio